USFDA14 May 2025, 08:41 pm
Shilpa Medicare's Subsidiary Shilpa Pharma Lifesciences Limited, Unit-1 Receives EIR from USFDA
AI Summary
Shilpa Medicare Limited's 100% subsidiary, Shilpa Pharma Lifesciences Limited, Unit-1, has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA). The site is now classified as Voluntary Action Indicated (VAI). The USFDA inspection took place at Unit-1 from March 3-7, 2025.
Key Highlights
- Shilpa Medicare's subsidiary, Shilpa Pharma Lifesciences Limited, Unit-1, receives EIR from USFDA
- Site classified as Voluntary Action Indicated (VAI) by USFDA
- USFDA inspection conducted at Unit-1 from March 3-7, 2025